2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To test the selectivity and degree of functional agonism of Ocelot Bio’s dual agonist/antagonist molecule, OCE-205, at the vasopressin 1a receptor (V1aR).

          Methods

          Cells expressing human (h) or rat V1a, V1b, V2, or oxytocin receptors (OTR) were incubated with varying concentrations of OCE-205 or with arginine vasopressin (AVP), and responses were measured with fluorescence or reporter gene assays. In addition, human resistance arteries were exposed to increasing concentrations of OCE-205, and the resulting contractility was measured.

          Results

          The mean efficacy of OCE-205 at hV1aR was 39% of the maximal possible effect (MPE), with a mean EC 50 of 0.71 nM. Above 1 nM OCE-205, the percent maximal possible effect (%MPE) plateaued. The EC 50 was much higher at hV1bR (134 nM), hV2R (420 nM), and OTR (6.9 nM), indicating selectivity for hV1aR. Results at rat receptors were similar. OCE-205 produced 40.0% of maximal depolarization-induced contraction, demonstrating functional partial agonism.

          Conclusion

          The dual agonist/antagonist structure of OCE-205 thus allows it to act as a highly selective partial agonist at vasopressin V1aR at therapeutically relevant concentrations.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Diagnosis, evaluation, and management of ascites and hepatorenal syndrome

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

              Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS. A prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin was performed. Subjects with type 1 HRS were randomized to terlipressin (1 mg intravenously every 6 hours) or placebo plus albumin in both groups. The dose was doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline. Treatment was continued to day 14 unless treatment success, death, dialysis, or transplantation occurred. Treatment success was defined by a decrease in SCr level to
                Bookmark

                Author and article information

                Journal
                Journal of Pharmacology and Pharmacotherapeutics
                Journal of Pharmacology and Pharmacotherapeutics
                SAGE Publications
                0976-500X
                0976-5018
                March 2023
                July 20 2023
                March 2023
                : 14
                : 1
                : 54-61
                Affiliations
                [1 ]Ferring Research Institute, San Diego, California, USA
                [2 ]Ocelot Bio Inc., San Diego, California, USA
                Article
                10.1177/0976500X231175220
                ce6eaaea-e27f-47f7-954e-71cea7da6380
                © 2023

                https://creativecommons.org/licenses/by-nc/4.0/

                History

                Comments

                Comment on this article